1.
Eight-year-old survives rabies
CAMBRIDGE, England, Oct. 23 (UPI) -- A drug initially designed to treat a form of leukemia has also proven effective against multiple sclerosis, British researchers said.
Researchers led by the University of Cambridge found that the drug alemtuzumab not only stops MS from advancing in patients with early stage active relapsing-remitting multiple sclerosis, or RRMS, but may also restore lost function caused by the disease.
The study found alemtuzumab reduces the number of attacks experienced by people with relapsing-remitting multiple sclerosis by 74 percent over and above that achieved with interferon beta-1a, one of the most effective licensed therapies for similar cases of MS.
However, alemtuzumab also reduced the risk of sustained accumulation of disability by 71 percent compared to interferon beta-1a.
Additionally, the investigators showed that many individuals in the trial who received alemtuzumab recovered some lost function and were less disabled after three years than at the beginning of the study, in contrast to worsening disability in the interferon beta-1a treated patients.
The findings are published in the New England Journal of Medicine.
|
|
|
| Additional Health News Stories | |
PORT EVERGLADES, Fla., Feb. 8 (UPI) --
A cruise ship that has been through one outbreak of a gastrointestinal virus was headed back to Florida on Wednesday after a second outbreak, its owner said.
|
LOS ANGELES, Feb. 8 (UPI) --
Pop star Katy Perry and comedian Russell Brand informed Los Angeles Superior Court they have reached a settlement in their divorce, documents show.
|
KARACHI, Pakistan, Feb. 8 (UPI) --
Experts said the carcass of a giant whale shark that washed ashore at Pakistan's Karachi Harbor likely got lost and became trapped in the shallow waters.
|
WASHINGTON, Feb. 8 (UPI) --
Thousands of tiny unmanned aircraft or drones flying into civilian airspace over the United States can pose a security threat as they may be difficult to monitor in the long run and some craft may fall into enemy hands, security analysts say.
|
| Stories | Photos | People | Comments |
View Caption
